News & Updates

In individuals experiencing dyspnoea after sustaining a SARS-CoV-2 infection, physiotherapy, particularly pulmonary rehabilitation, may be beneficial in mitigating respiratory symptoms, according to the results of a systematic review and meta-analysis.

New drug applications approved by US FDA as of 1-15 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The apnoea-hypopnoea index (AHI) shows a positive association with age and a negative association with facial axis angle, reports a Singapore study involving Southeast Asian Chinese patients with obstructive sleep apnoea (OSA).

Patients with chronic obstructive pulmonary disease (COPD) are at heightened risk of myocardial infarction (MI) and pulmonary embolism (PE) in the presence of acute exacerbations, according to a study.

In the treatment of hospitalized adults with COVID-19 and hypoxemia, the use of the spleen tyrosine kinase inhibitor fostamatinib does not appear to have any positive effect on the number of oxygen-free days as compared with placebo, according to the results of a phase III trial.

Prolonged air purification in indoor environments helps alleviate airway inflammation in children, a study has shown.

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.